FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

Rhea-AI Summary

Insmed (INSM) received FDA Priority Review for its supplemental New Drug Application (sNDA) seeking full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen, with a PDUFA target action date of January 28, 2027.

The filing aims to move ARIKAYCE use earlier in the disease course, including newly diagnosed and recurrent infections, and would also fulfill the post‑marketing requirement from ARIKAYCE’s 2018 accelerated approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs. The sNDA is supported by the randomized, double‑blind, placebo‑controlled Phase 3b ENCORE study in 425 treatment‑naïve MAC lung disease patients, where ARIKAYCE plus multidrug therapy met its primary endpoint of improved Respiratory Symptom Score at Month 13 and multiplicity‑controlled secondary culture conversion endpoints versus multidrug therapy alone, with a safety profile consistent with prior experience. Insmed plans to discuss ENCORE data with Japan’s PMDA in Q4 2026 for potential label expansion.

Positive

• Priority Review granted for ARIKAYCE sNDA with PDUFA date January 28, 2027
• Phase 3b ENCORE met primary RSS endpoint and key culture conversion endpoints
• 425 patients enrolled across 177 global sites in ENCORE study
• 2018 accelerated approval post‑marketing requirement supported by ENCORE results
• Global opportunity: ENCORE data to be reviewed with Japan PMDA in Q4 2026

Negative

• Respiratory adverse reactions increased vs background: bronchospasm 28.7% vs 10.7%, hemoptysis 17.9% vs 12.5%
• Hypersensitivity pneumonitis 3.1% with ARIKAYCE vs 0% with background regimen alone
• Ototoxicity events 17% with ARIKAYCE vs 9.8% with background regimen alone
• Common side effects such as dysphonia 47% vs 1% and cough 39% vs 17% in Trial 1
• Current U.S. label limited to adults with refractory MAC and limited or no alternatives under accelerated approval
• Embryo‑fetal toxicity risk including potential irreversible bilateral congenital deafness with in utero exposure

Key Figures

PDUFA target action date: January 28, 2027 Enrollment: 425 patients Study sites: 177 sites +3 more

PDUFA target action date

January 28, 2027

ARIKAYCE sNDA Priority Review

Enrollment

425 patients

Phase 3b ENCORE study

Study sites

177 sites

Phase 3b ENCORE study

Treatment duration

12 months

ARIKAYCE plus multidrug therapy or placebo plus multidrug therapy

Post-treatment assessment

3 months

Durability of culture conversion

Randomization

1:1

ARIKAYCE and comparator arms

Key Terms

sndA, priority review, pdufa, accelerated approval, +2 more

6 terms

sndA regulatory

"accepted the Company's Supplemental New Drug Application (sNDA) for review"

A SNDA (Subordination, Non‑Disturbance and Attornment Agreement) is a legal pact among a property owner’s lender, the owner’s tenants, and sometimes the landlord that sets who keeps lease rights if the property is sold or a mortgage is enforced. Think of it as a rulebook that decides whether a tenant can stay and keep paying rent or must answer to a new owner after a foreclosure. For investors, an SNDA matters because it protects predictable rental income, clarifies who has priority on claims against a property, and therefore affects a property’s value and the security of related loans.

priority review regulatory

"the FDA granted Priority Review to the sNDA"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

pdufa regulatory

"under the Prescription Drug User Fee Act (PDUFA)"

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

accelerated approval regulatory

"ARIKAYCE received FDA accelerated approval in 2018"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

post-marketing requirement regulatory

"fulfill the post-marketing requirement associated with ARIKAYCE's accelerated approval"

A post-marketing requirement is a regulatory obligation for a company to collect more safety or effectiveness data after a product is approved and sold, similar to a follow-up check after permission is granted. Investors care because these required studies or reports can affect future sales, trigger label changes, additional costs, or even regulatory action if new risks emerge, so they influence a product’s long-term revenue and company risk profile.

multiplicity-controlled technical

"met its primary endpoint and multiplicity-controlled secondary culture conversion endpoints"

A multiplicity-controlled analysis is a statistical approach that adjusts how results are judged when many hypotheses or comparisons are tested at once, so that the chance of finding false positives by coincidence stays low. Think of it as tightening the rules when you flip many coins so you don’t mistake random heads for a real pattern; for investors, it matters because conclusions about safety, efficacy, or financial signals are less likely to be driven by chance when multiplicity is controlled.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study—

—Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA— 

BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE^® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. In its communication to Insmed, the FDA granted Priority Review to the sNDA and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).

"The FDA's acceptance of this application marks a pivotal moment in our ambition to change the treatment paradigm for MAC lung disease," said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. "MAC lung disease is progressive — the longer the infection persists, the greater the damage to lung tissue and the harder it becomes to treat. If full approval is granted, ARIKAYCE could reach patients earlier in their disease course, including those newly diagnosed or facing recurrent infections. We look forward to engaging with the FDA throughout the review process."

The FDA grants Priority Review to applications for medicines that, if approved, would provide a significant improvement in safety or effectiveness in the treatment of a serious condition.

ARIKAYCE received FDA accelerated approval in 2018 for refractory MAC lung disease and was the first product approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) — a pathway enacted under the 21st Century Cures Act to advance the development of antibacterial therapies for serious or life-threatening infections in patients with unmet needs.

The sNDA for full approval is supported by results from the Phase 3b ENCORE study, the pivotal study conducted to fulfill the post-marketing requirement associated with ARIKAYCE's accelerated approval. ENCORE met its primary endpoint and multiplicity-controlled secondary culture conversion endpoints, with ARIKAYCE plus multidrug therapy demonstrating statistically significant improvements in respiratory symptoms and culture conversion in adults with MAC lung disease compared to multidrug therapy alone.

Insmed also plans to review the ENCORE data with the Pharmaceuticals and Medical Devices Agency (PMDA) in the fourth quarter of 2026 to support potential label expansion in Japan.

About the Phase 3b ENCORE Study

ENCORE was a randomized, double-blind, placebo-controlled, Phase 3b study to evaluate the efficacy and safety of ARIKAYCE plus multidrug therapy in patients with a new occurrence of MAC lung infection who had not received antibiotics. The study enrolled 425 patients across 177 sites globally, including patients experiencing their first MAC infection (82.4%) or their second or third infection (17.6%). Patients were randomized 1:1 to receive once-daily ARIKAYCE plus multidrug therapy (azithromycin 250 mg + ethambutol 15 mg/kg; n=213) or placebo plus multidrug therapy (azithromycin 250 mg + ethambutol 15 mg/kg; n=212) for 12 months, followed by three months off treatment to assess durability of culture conversion.

The primary endpoint was change from baseline in Respiratory Symptom Score (RSS) at Month 13. The study met its primary endpoint and its multiplicity-controlled secondary culture conversion endpoints, demonstrating statistically significant improvements in respiratory symptoms and culture conversion. Patients treated with ARIKAYCE achieved earlier, greater and more durable culture conversion than those receiving comparator therapy, and the safety profile was consistent with the known safety profile of ARIKAYCE, with no new safety signals observed.

About MAC Lung Disease

Mycobacterium avium complex (MAC) lung disease is a rare and serious disease that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen over time, including chronic cough, dyspnea, fatigue, fever, weight loss, and chest pain. In some cases, MAC lung disease can cause severe, even permanent damage to the lungs, and can be fatal. MAC lung disease is an emerging public health concern worldwide with significant unmet need.

About ARIKAYCE 

ARIKAYCE^® is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE™ liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira^® Nebulizer System manufactured by PARI Pharma GmbH (PARI). 

About PARI Pharma and the Lamira^® Nebulizer System 

ARIKAYCE is delivered by a novel inhalation device, the Lamira^® Nebulizer System, developed by PARI. Lamira^® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care. 

BOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS ARIKAYCE has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation ofunderlying pulmonary disease that have led to hospitalizations in some cases.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If hemoptysis occurs, manage patients as medically appropriate.

Bronchospasm has been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%) compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate. 

Exacerbations of underlying pulmonary disease has been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions: Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

Ototoxicity has been reported with the use of ARIKAYCE in the clinical trials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo) were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated with background regimen alone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9% in the background regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the background regimen alone arm). Closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment with ARIKAYCE. If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.

Nephrotoxicity was observed during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been associated with the aminoglycosides. Close monitoring of patients with known or suspected renal dysfunction may be needed when prescribing ARIKAYCE.

Neuromuscular Blockade: Patients with neuromuscular disorders were not enrolled in ARIKAYCE clinical trials. Patients with known or suspected neuromuscular disorders, such as myasthenia gravis, should be closely monitored since aminoglycosides may aggravate muscle weakness by blocking the release of acetylcholine at neuromuscular junctions.

Embryo-Fetal Toxicity: Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated with total, irreversible, bilateral congenital deafness in pediatric patients exposed in utero. Patients who use ARIKAYCE during pregnancy, or become pregnant while taking ARIKAYCE should be apprised of the potential hazard to the fetus.

Contraindications: ARIKAYCE is contraindicated in patients with known hypersensitivity to any aminoglycoside.

Most Common Adverse Reactions: The most common adverse reactions in Trial 1 at an incidence ≥5% for patients using ARIKAYCE plus background regimen compared to patients treated with background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs 1%), and chest discomfort (5% vs 3%).

Drug Interactions: Avoid concomitant use of ARIKAYCE with medications associated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or intravenous mannitol.

Overdosage: Adverse reactions specifically associated with overdose of ARIKAYCE have not been identified. Acute toxicity should be treated with immediate withdrawal of ARIKAYCE, and baseline tests of renal function should be undertaken. Hemodialysis may be helpful in removing amikacin from the body. In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment.

U.S. INDICATION 

LIMITED POPULATION: ARIKAYCE^® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.

This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitation of Use:

ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Patients are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call the Company at 1-844-4-INSMED. 

Please see Full Prescribing Information. 

About Insmed 

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: risk that topline data from the Company's clinical trials, including the ENCORE study, that the Company announces or publishes from time to time may change as more patient data become available or may be interpreted differently if additional data are disclosed; failure to continue to successfully commercialize ARIKAYCE in the U.S., Europe or Japan, or to maintain U.S., European or Japanese approval for ARIKAYCE; the Company's inability to obtain full approval of ARIKAYCE from the FDA, or the Company's failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside of the U.S., Europe and Japan, including separate regulatory approval for the Lamira^® Nebulizer System in each market and for each usage; failure to successfully commercialize ARIKAYCE in a broader patient population, if approved by applicable regulatory authorities; uncertainties or changes in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community; the Company's inability to obtain and maintain adequate reimbursement from government or third-party payors for ARIKAYCE in a broader patient population, if approved, or acceptable prices for ARIKAYCE; inaccuracies in the Company's estimates of the size of the potential markets for ARIKAYCE or in data the Company has used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; failure of third parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE for commercial needs, or to comply with the Company's agreements or laws and regulations that impact the Company's business; the Company's inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; development of unexpected safety or efficacy concerns related to ARIKAYCE; restrictions or other obligations imposed on the Company by agreements related to ARIKAYCE, including the Company's license agreement with PARI, and failure to comply with the Company's obligations under such agreements; the cost and potential reputational damage resulting from litigation to which the Company is or may become a party, including product liability claims; and delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Company filings with the Securities and Exchange Commission (SEC).

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contacts

Investors:
Sara Bonstein
Chief Financial Officer
investor.relations@insmed.com 

Media:
Claire Mulhearn
Vice President, Corporate Communications
media@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-insmeds-snda-for-arikayce-amikacin-liposome-inhalation-suspension-for-treatment-of-mac-lung-disease-with-pdufa-target-action-date-set-for-january-28-2027-302884017.html

SOURCE Insmed Incorporated

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What patient population was studied in the Phase 3b ENCORE trial of ARIKAYCE?

ENCORE enrolled 425 adults with a new occurrence of MAC lung infection who had not received antibiotics. Of these, 82.4% were experiencing their first MAC infection and 17.6% were experiencing their second or third infection. Patients were randomized 1:1 to once‑daily ARIKAYCE plus multidrug therapy (azithromycin 250 mg + ethambutol 15 mg/kg; n=213) or placebo plus the same multidrug therapy (n=212) for 12 months, followed by three months off treatment to assess durability of culture conversion.

What were the key efficacy outcomes from the ENCORE study supporting the sNDA?

The primary endpoint was change from baseline in Respiratory Symptom Score (RSS) at Month 13. ENCORE met this primary endpoint and its multiplicity‑controlled secondary culture conversion endpoints. Patients receiving ARIKAYCE plus multidrug therapy showed statistically significant improvements in respiratory symptoms and culture conversion versus multidrug therapy alone, achieving earlier, greater, and more durable culture conversion.

What is ARIKAYCE’s current U.S. indication and how is it limited?

In the United States, ARIKAYCE is indicated in adults with MAC lung disease who have limited or no alternative treatment options, as part of a combination regimen, when they do not achieve negative sputum cultures after at least six consecutive months of a multidrug background regimen. The indication is approved under accelerated approval based on sputum culture conversion by Month 6, and clinical benefit has not yet been established. Continued approval may depend on verification of clinical benefit in confirmatory trials, and use is not recommended in non‑refractory MAC lung disease.

What major safety warnings accompany ARIKAYCE in the U.S. label?

ARIKAYCE carries a boxed warning for an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease, some leading to hospitalization. Other warnings include serious hypersensitivity and anaphylaxis, ototoxicity, nephrotoxicity, potential neuromuscular blockade in susceptible patients, and embryo‑fetal toxicity, including the risk of irreversible, bilateral congenital deafness with in utero exposure.

How is ARIKAYCE administered and what technology does it use?

ARIKAYCE is a once‑daily inhaled formulation of amikacin delivered directly to the lungs using Insmed’s PULMOVANCE liposomal technology, which enables uptake by lung macrophages where infection resides while limiting systemic exposure. It is administered via the Lamira Nebulizer System, a portable device developed by PARI Pharma that uses a vibrating, perforated membrane to aerosolize ARIKAYCE.